Study of DNL952 for adults with late-onset Pompe disease
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests a new drug, DNL952, in adults with late-onset Pompe disease. It aims to see if the drug is safe and how it works in the body, with different groups for people currently on enzyme replacement therapy or those who haven't had it in the past year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must weigh at least 40 kilograms (about 88 pounds).
- You have been diagnosed with late-onset Pompe disease.
- Your lung function (measured by FVC) is at least 30% of what is expected for someone your age and height.
- You can walk at least 40 meters (about 130 feet), with or without a walker or cane.
- If you are in Group A, you must have been on one of two standard enzyme replacement therapies (every two weeks) for at least the last year.
- If you are in Group B, you must not have had any enzyme replacement therapy for Pompe disease in the last year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication, S-606001, given alongside your current enzyme replacement therapy (ERT) for late-onset Pompe disease. It may help improve your breathing and walking ability.
This trial tests an experimental medication called S-606001 for people with late-onset Pompe disease. The goal is to see if it can help improve breathing and walking ability. Participants must not have received enzyme replacement therapy for at least 3 months before starting.
This trial tests a new gene therapy for late-onset Pompe disease. It aims to see if the treatment is safe and effective, and might provide a long-term alternative to enzyme replacement therapy.
This trial tests a new gene therapy for late-onset Pompe disease. The therapy aims to help your body produce the enzyme needed to break down glycogen, which may improve muscle and breathing function.
This study tests whether adults with late-onset Pompe disease can safely receive their enzyme replacement therapy less often, every 4 weeks instead of every 2 weeks, while maintaining stability. It aims to see if a lower treatment frequency is just as effective and improves quality of life.
This study tests a one-time gene therapy (AB-1009) for adults with late-onset Pompe disease. It aims to see if the treatment is safe and improves muscle and breathing function.
Hear when a new Late-onset Pompe Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.